Heart Attack Treatment (cont.)
Daniel Lee Kulick, MD, FACC, FSCAI
Daniel Lee Kulick, MD, FACC, FSCAI
Dr. Kulick received his undergraduate and medical degrees from the University of Southern California, School of Medicine. He performed his residency in internal medicine at the Harbor-University of California Los Angeles Medical Center and a fellowship in the section of cardiology at the Los Angeles County-University of Southern California Medical Center. He is board certified in Internal Medicine and Cardiology.
In this Article
Coronary artery stents
Coronary artery stents are small hollow cylinders that can be deployed over the angioplasty balloons and left within the coronary arteries to keep the arteries open. Stents help prevent abrupt closure of arteries shortly after PTCA. They also prevent restenosis (recurrent narrowing of the arteries) several months after PTCA.
Coronary stents decrease the risks of arterial dissections, elastic recoil, and artery spasm that can occur after PTCA and cause re-occlusion of the artery. Studies have shown that the incidence of abrupt coronary artery closure after PTCA has declined dramatically with the introduction of coronary stents.
Coronary stents also help to keep the coronary arteries open in the longer-term. After a successful PTCA, as many as 30% to 40% of patients will develop recurrent narrowing (restenosis) at the site of inflation of the balloon, usually within 6 months following PTCA. Restenosis may or may not be accompanied by symptoms such as angina. Thus, restenosis often is detected by exercise stress tests performed 4 to 6 months after PTCA. The widespread use of coronary stents has reduced this incidence of restenosis by as much as 50%. The recent introduction of coated stents (stents that are coated with chemicals to further reduce restenosis) has reduced the incidence of restenosis to well under 10% and has been a major improvement in treatment.
Patients with coronary artery stents usually are maintained on full doses of daily aspirin. For the first 4 to 12 weeks after the placement of stents, patients are given an additional antiplatelet drug such as clopidogrel or prasugrel because the metal surface of the stents may promote the formation of blood clots in the first several weeks after the stent is inserted. With the newer medicated stents, aspirin and clopidogrel or prasugrel are continued for a year or longer.
Reviewed by Jay W. Marks, MD on 8/24/2012
Viewers share their comments
Heart Attack Treatment - Aspirin Question: Do you take aspirin to prevent a first or second heart attack? Please share your experience.
Heart Attack Treatment - Types of Treatment Question: What kinds of treatment, procedures, surgeries, or medications have you received after experiencing a heart attack?
Heart Attack Treatment - Angiography or Angioplasty Question: Please discuss your experience with coronary angiography and PTCA.
Heart Attack Treatment - Coronary Artery Bypass Question: Did you have coronary artery bypass surgery? Please share your story.
Heart Attack Treatment - Preventing a Second Attack Question: If you've had a heart attack, what lifestyle changes have you made to prevent a second heart attack?
Heart Attack - Experience Question: Please describe your experience with a heart attack.
Heart Attack - Symptoms Question: What were your heart attack symptoms?
Get the latest health and medical information delivered direct to your inbox FREE!